X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (803) 803
Publication (79) 79
Book Review (11) 11
Book Chapter (5) 5
Dissertation (2) 2
Conference Proceeding (1) 1
Magazine Article (1) 1
Newspaper Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (689) 689
index medicus (471) 471
oncology (401) 401
female (342) 342
cancer (246) 246
genes, erbb-1 (206) 206
male (206) 206
mutation (203) 203
animals (200) 200
middle aged (193) 193
aged (178) 178
epidermal growth factor (173) 173
lung neoplasms - genetics (157) 157
gefitinib (156) 156
lung neoplasms - drug therapy (151) 151
genes, erbb-1 - genetics (149) 149
antineoplastic agents - therapeutic use (148) 148
chemotherapy (145) 145
expression (143) 143
gene expression (142) 142
genetic aspects (141) 141
growth-factor receptor (140) 140
adult (139) 139
care and treatment (138) 138
breast cancer (137) 137
research (136) 136
cell line, tumor (135) 135
carcinoma, non-small-cell lung - drug therapy (132) 132
egfr (129) 129
receptor, epidermal growth factor - genetics (129) 129
tumors (121) 121
carcinoma, non-small-cell lung - genetics (120) 120
mice (113) 113
prognosis (113) 113
lung cancer (102) 102
signal transduction (100) 100
kinases (96) 96
receptor, epidermal growth factor - metabolism (96) 96
erlotinib (95) 95
quinazolines - therapeutic use (95) 95
receptor, epidermal growth factor - antagonists & inhibitors (95) 95
immunohistochemistry (92) 92
analysis (91) 91
lung neoplasms - pathology (90) 90
apoptosis (87) 87
gene expression regulation, neoplastic (87) 87
health aspects (86) 86
proteins (86) 86
gene amplification (82) 82
lung cancer, non-small cell (80) 80
aged, 80 and over (77) 77
treatment outcome (77) 77
medicine & public health (75) 75
signal transduction - drug effects (75) 75
breast neoplasms - genetics (74) 74
protein kinase inhibitors - therapeutic use (74) 74
cell lung-cancer (72) 72
epidermal growth factor receptor (72) 72
phosphorylation (72) 72
survival (72) 72
antineoplastic agents - pharmacology (70) 70
breast neoplasms - drug therapy (70) 70
cell biology (70) 70
therapy (70) 70
biochemistry & molecular biology (68) 68
epidermal growth factor receptors (68) 68
tyrosine (68) 68
breast-cancer (67) 67
cancer therapies (66) 66
receptor, erbb-2 - metabolism (66) 66
research article (66) 66
breast neoplasms - pathology (65) 65
tyrosine kinase inhibitor (64) 64
metastasis (63) 63
pharmacology & pharmacy (61) 61
article (60) 60
breast neoplasms - metabolism (60) 60
epidermal-growth-factor (60) 60
carcinoma, non-small-cell lung - pathology (59) 59
development and progression (59) 59
hematology, oncology and palliative medicine (59) 59
pathology (59) 59
adenocarcinoma - genetics (58) 58
erlotinib hydrochloride (58) 58
growth-factor-receptor (58) 58
disease-free survival (57) 57
adenocarcinoma (56) 56
genes (56) 56
medicine (56) 56
antineoplastic combined chemotherapy protocols - therapeutic use (55) 55
genes, erbb-1 - drug effects (54) 54
quinazolines - pharmacology (54) 54
acquired-resistance (53) 53
drug resistance, neoplasm - genetics (51) 51
medical prognosis (51) 51
survival analysis (51) 51
gene copy number (50) 50
activation (49) 49
neoplasm staging (48) 48
receptor, erbb-2 - genetics (48) 48
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 08/2011, Volume 6, Issue 8, p. e23894
Background: Betacellulin (BTC), a member of the epidermal growth factor family, is known to play an important role in regulating growth and differentiation of... 
DIABETIC MICE | NEOGENESIS | EPIDERMAL-GROWTH-FACTOR | BIOLOGY | INSULIN-SECRETING CELLS | DIFFERENTIATION | UP-REGULATION | AR42J CELLS | EXPRESSION | CARDIAC DEVELOPMENT | EGF RECEPTOR | Diabetes Mellitus - pathology | Cell Line | Receptor, ErbB-2 - metabolism | Diabetes Mellitus - metabolism | Insulin Receptor Substrate Proteins - metabolism | Enzyme Activation - drug effects | Gene Expression Regulation - drug effects | Insulin-Secreting Cells - metabolism | Receptor, Epidermal Growth Factor - metabolism | Animals | Betacellulin | Insulin-Secreting Cells - drug effects | Intercellular Signaling Peptides and Proteins - pharmacology | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Cell Proliferation - drug effects | Insulin-Secreting Cells - cytology | Mice | Receptor, ErbB-2 - antagonists & inhibitors | Insulin Receptor Substrate Proteins - genetics | Tyrosine | Pancreatic beta cells | Epidermal growth factor | RNA | Analysis | Adenoviruses | Cell proliferation | Phosphorylation | Immunoprecipitation | Bromodeoxyuridine | Activation | mRNA | Glucose | Kinases | Western blotting | Receptors | Cell growth | ErbB-4 protein | Rodents | Cell cycle | Remission | Pancreas | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Recombinant | ErbB-1 protein | Epidermal growth factor receptors | ErbB protein | Diabetes mellitus | siRNA | ErbB-3 protein | Growth factor receptors | Gene expression | Insulin | ErbB-2 protein | Substrates | Beta cells | Polymerase chain reaction | Regeneration | Molecular modelling | Inhibitors | Islets of Langerhans | Deoxyribonucleic acid | DNA
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2017, Volume 18, Issue 11, pp. 1454 - 1466
Journal Article
by Mok, Tony S K and Wu, Yi-Long and Kudaba, Iveta and Kowalski, Dariusz M and Cho, Byoung Chul and Turna, Hande Z and Castro, Gilberto and Srimuninnimit, Vichien and Laktionov, Konstantin K and Bondarenko, Igor and Kubota, Kaoru and Lubiniecki, Gregory M and Zhang, Jin and Kush, Debra and Lopes, Gilberto and Adamchuk, Grigory and Ahn, Myung-Ju and Alexandru, Aurelia and Altundag, Ozden and Alyasova, Anna and Andrusenko, Orest and Aoe, Keisuke and Araujo, Antonio and Aren, Osvaldo and Arrieta Rodriguez, Oscar and Ativitavas, Touch and Avendano, Oscar and Barata, Fernando and Barrios, Carlos Henrique and Beato, Carlos and Bergstrom, Per and Betticher, Daniel and Bolotina, Larisa and Bondarenko, Igor and Botha, Michiel and Buddu, Sayeuri and Caglevic, Christian and Cardona, Andres and Castro, Gilberto and Castro, Hugo and Cay Senler, Filiz and Cerny, Carlos Alexandre Sydow and Cesas, Alvydas and Chan, Gee-Chen and Chang, Jianhua and Chen, Gongyan and Chen, Xi and Cheng, Susanna and Cheng, Ying and Cherciu, Nelly and Chiu, Chao-Hua and Cho, Byoung Chul and Cicenas, Saulius and Ciurescu, Daniel and Cohen, Graham and Costa, Marcos Andre and Danchaivijitr, Pongwut and De Angelis, Flavia and de Azevedo, Sergio Jobim and Dediu, Mircea and Deliverski, Tsvetan and De Marchi, Pedro Rafael Martins and de The Bustamante Valles, Flor and Ding, Zhenyu and Doganov, Boyan and Dreosti, Lydia and Duarte, Ricardo and Edusma-Dy, Regina and Emelyanov, Sergey and Erman, Mustafa and Fan, Yun and Fein, Luis and Feng, Jifeng and Fenton, David and Fernandes, Gustavo and Ferreira, Carlos and Franke, Fabio Andre and Freitas, Helano and Fujisaka, Yasuhito and Galindo, Hector and Galvez, Christina and Ganea, Doina and Gil, Nuno and Girotto, Gustavo and Goker, Erdem and Goksel, Tuncay and Gomez Aubin, Gonzalo and Gomez Wolff, Luis and Griph, Hakan and Gumus, Mahmut and Hall, Jacqueline and Hart, Gregory and Havel, Libor and He, Jianxing and He, Yong and Hernandez Hernandez, Carlos and Hespanhol, Venceslau and Hirashima, Tomonori and Ho, Chung Man James and Horiike, Atsushi and ... and KEYNOTE-042 Investigators
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10183, pp. 1819 - 1830
First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a... 
MEDICINE, GENERAL & INTERNAL | CARBOPLATIN | GEFITINIB | BEVACIZUMAB | CRIZOTINIB | NIVOLUMAB | PACLITAXEL | Genes, erbB-1 - drug effects | Lung Neoplasms - drug therapy | Translocation, Genetic | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Lung Neoplasms - metabolism | Middle Aged | Far East - epidemiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Anaplastic Lymphoma Kinase - genetics | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Non-Small-Cell Lung - secondary | Lung Neoplasms - secondary | Female | Carcinoma, Non-Small-Cell Lung - pathology | Anaplastic Lymphoma Kinase - drug effects | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Genes, erbB-1 - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Disease-Free Survival | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Metastasis - pathology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Chemotherapy | Metastasis | Lung cancer, Non-small cell | Cancer | Lung cancer | Oncology | Kinases | Cancer therapies | Evidence-based medicine | Metastases | Pembrolizumab | Randomization | Motivation | Platinum | Risk assessment | Population | Translocation | Cell survival | Life expectancy | Epidermal growth factor receptors | Hyperthyroidism | Histology | Health care facilities | Hypothyroidism | Survival | Patients | Life span | Interactive systems | PD-L1 protein | Men | Ligands | Tumors | Apoptosis
Journal Article
Annals of Oncology, ISSN 0923-7534, 2/2009, Volume 20, Issue 2, pp. 298 - 304
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 24, pp. 2288 - 2301
The addition of atezolizumab (anti–PD-L1 antibody) to a platinum-based chemotherapy regimen improved progression-free survival among patients who had not... 
PHASE-III TRIAL | CELLS | MULTICENTER | THERAPY | BEVACIZUMAB | ANTIBODY | OPEN-LABEL | CANCER | DOCETAXEL | CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Neoplasm Metastasis - drug therapy | Immunotherapy | Female | Paclitaxel - administration & dosage | Bevacizumab - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Carboplatin - administration & dosage | Carcinoma, Non-Small-Cell Lung - mortality | Genes, erbB-1 | B7-H1 Antigen - antagonists & inhibitors | Receptor Protein-Tyrosine Kinases - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Lung cancer, Non-small cell | Drug therapy | Research | Epidermal growth factor receptors | Liver | Non-small cell lung carcinoma | Oncology | Lymphocytes T | Metastasis | Cancer therapies | Patients | Bevacizumab | Metastases | Immunosuppression | Chemotherapy | Motivation | Medical prognosis | PD-L1 protein | Paclitaxel | Carboplatin | Population | Death | Vascular endothelial growth factor | Genotypes | Apoptosis | Tumors
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2012, Volume 30, Issue 10, pp. 1122 - 1128
Journal Article